Compulsory licenses are an option when pricing negotiations with the makers of hepatitis C drugs are not successful, according to a report by the Global Commission on Drug Policy. "Governments, international bodies and civil society organizations should seek to replicate the successful reduction in HIV treatment costs around the world, including the use of patent law flexibilities to make them more accessible," the report said. Patient advocates say compulsory licenses are needed to make treatments affordable. The makers of branded drugs say the plan removes incentives for research that leads to innovative treatments.

Full Story:

Related Summaries